CL2019001530A1 - Anticuerpos y polipéptidos dirigidos contra cd127. - Google Patents

Anticuerpos y polipéptidos dirigidos contra cd127.

Info

Publication number
CL2019001530A1
CL2019001530A1 CL2019001530A CL2019001530A CL2019001530A1 CL 2019001530 A1 CL2019001530 A1 CL 2019001530A1 CL 2019001530 A CL2019001530 A CL 2019001530A CL 2019001530 A CL2019001530 A CL 2019001530A CL 2019001530 A1 CL2019001530 A1 CL 2019001530A1
Authority
CL
Chile
Prior art keywords
antibodies
directed against
polypeptides directed
humanized
polypeptides
Prior art date
Application number
CL2019001530A
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Virginie Thepenier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of CL2019001530A1 publication Critical patent/CL2019001530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCIÓN SE ENCUENTRA EL CAMPO DE LOS ANTICUERPOS ÚTILES EN APLICACIONES TERAPÉUTICAS Y DE DIAGNÓSTICO CON DIANA EN CD127, LA CADENA ALFA DEL RECEPTOR DE IL7, Y PROVEE EN PARTICULAR, ANTICUERPOS MONOCLONALES HUMANIZADOS CONTRA CD127, PARTICULARMENTE CD127 HUMANO, SUS USOS TERAPÉUTICOS Y APLICACIONES DE TIPO DIAGNÓSTICO.
CL2019001530A 2016-12-09 2019-06-05 Anticuerpos y polipéptidos dirigidos contra cd127. CL2019001530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306655 2016-12-09

Publications (1)

Publication Number Publication Date
CL2019001530A1 true CL2019001530A1 (es) 2019-10-11

Family

ID=57796143

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001530A CL2019001530A1 (es) 2016-12-09 2019-06-05 Anticuerpos y polipéptidos dirigidos contra cd127.

Country Status (37)

Country Link
US (2) US11098128B2 (es)
EP (1) EP3551664B1 (es)
JP (1) JP6986559B2 (es)
KR (1) KR102306366B1 (es)
CN (1) CN110392695B (es)
AR (1) AR110326A1 (es)
AU (1) AU2017373819B2 (es)
BR (1) BR112019010595A2 (es)
CA (1) CA3042582C (es)
CL (1) CL2019001530A1 (es)
CO (1) CO2019005909A2 (es)
CR (1) CR20190273A (es)
CY (1) CY1124153T1 (es)
DK (1) DK3551664T3 (es)
EA (1) EA201991005A1 (es)
ES (1) ES2867900T3 (es)
HR (1) HRP20210697T1 (es)
HU (1) HUE054206T2 (es)
IL (1) IL266837B (es)
LT (1) LT3551664T (es)
MA (1) MA49727B1 (es)
MD (1) MD3551664T2 (es)
MX (1) MX2019006577A (es)
MY (1) MY190770A (es)
NZ (1) NZ753213A (es)
PE (1) PE20191152A1 (es)
PH (1) PH12019501285A1 (es)
PL (1) PL3551664T3 (es)
PT (1) PT3551664T (es)
RS (1) RS61808B1 (es)
RU (1) RU2769352C2 (es)
SA (1) SA519401906B1 (es)
SI (1) SI3551664T1 (es)
TW (1) TWI777996B (es)
UA (1) UA126386C2 (es)
UY (1) UY37511A (es)
WO (1) WO2018104483A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018225062A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
BR112021014106A2 (pt) * 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) * 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
BR112022008744A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN113501499A (zh) * 2021-08-11 2021-10-15 无锡贝塔医药科技有限公司 一种高纯无水溴化氘气体的制备方法及其应用
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
KR20130028055A (ko) * 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
TWI552760B (zh) * 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
AR110326A1 (es) 2019-03-20
AU2017373819B2 (en) 2022-03-31
BR112019010595A2 (pt) 2019-09-17
RU2769352C2 (ru) 2022-03-30
KR102306366B1 (ko) 2021-09-29
MA49727B1 (fr) 2021-05-31
CN110392695B (zh) 2021-02-02
KR20190090005A (ko) 2019-07-31
MY190770A (en) 2022-05-12
DK3551664T3 (da) 2021-05-03
CA3042582C (en) 2023-05-23
PT3551664T (pt) 2021-04-21
CN110392695A (zh) 2019-10-29
UY37511A (es) 2018-06-29
IL266837A (en) 2019-07-31
EP3551664A1 (en) 2019-10-16
LT3551664T (lt) 2021-05-25
CY1124153T1 (el) 2022-05-27
UA126386C2 (uk) 2022-09-28
HRP20210697T1 (hr) 2021-07-23
RS61808B1 (sr) 2021-06-30
CR20190273A (es) 2019-10-17
CO2019005909A2 (es) 2019-07-31
NZ753213A (en) 2022-05-27
US20190375844A1 (en) 2019-12-12
MX2019006577A (es) 2019-10-07
RU2019115610A3 (es) 2021-04-05
US11098128B2 (en) 2021-08-24
EA201991005A1 (ru) 2019-12-30
US20210395376A1 (en) 2021-12-23
SA519401906B1 (ar) 2022-12-20
CA3042582A1 (en) 2018-06-14
RU2019115610A (ru) 2021-01-12
US20220332834A2 (en) 2022-10-20
IL266837B (en) 2020-06-30
TWI777996B (zh) 2022-09-21
AU2017373819A1 (en) 2019-05-30
JP2020500542A (ja) 2020-01-16
US11926671B2 (en) 2024-03-12
MA49727A (fr) 2019-10-16
WO2018104483A1 (en) 2018-06-14
TW201833137A (zh) 2018-09-16
PL3551664T3 (pl) 2021-08-02
EP3551664B1 (en) 2021-02-17
MD3551664T2 (ro) 2021-06-30
ES2867900T3 (es) 2021-10-21
HUE054206T2 (hu) 2021-08-30
JP6986559B2 (ja) 2022-01-05
PE20191152A1 (es) 2019-09-05
PH12019501285A1 (en) 2019-12-16
SI3551664T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2019001530A1 (es) Anticuerpos y polipéptidos dirigidos contra cd127.
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CL2018002792A1 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos.
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2018001202A1 (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
CL2016002247A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
MX2019008348A (es) Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
UY38309A (es) Receptores químericos de steap1 y métodos de uso de los mismos
EA201992883A1 (ru) АНТИТЕЛА К TrkB
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
IT201700115761A1 (it) Bioreattore per la ricellularizzazione e la stimolazione meccanica del diaframma
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
EA201990493A1 (ru) Антитела к гм-ксф и их применения
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
EA201990824A1 (ru) Антитела, которые связываются с интерлейкином-2, и их применение
EA201892257A1 (ru) Анти-cd3 антитела и способы применения